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Abstract
We have previously reported increased apoptosis of regulatory T cells (Tregs) in recent-onset Type 1 Diabetes subjects (RO
T1D) in the honeymoon phase and in multiple autoantibody-positive (Ab+) subjects, some of which are developing T1D. We
have also reported that increased Treg apoptosis was associated with High HLA risk and that it subsided with cessation of
honeymoon period. In this report, we present results generated using genetics, genomics, functional cell-based assays and
flow cytometry to assess cellular changes at the T-cell level during T1D pathogenesis. We measured ex vivo Treg apoptosis
and Treg function, surface markers expression, expression of HLA class II genes, the influence of HLA risk on Treg apoptosis
and function, and evaluated contribution of genes reported to be involved in the apoptosis process. This integrated
comprehensive approach uncovered important information that can serve as a basis for future studies aimed to modulate
Treg cell responsiveness to apoptotic signals in autoimmunity. For example, T1D will progress in those subjects where
increased Treg apoptosis is accompanied with decreased Treg function. Furthermore, Tregs from High HLA risk healthy
controls had increased Treg apoptosis levels and overexpressed FADD but not Fas/FasL. Tregs from RO T1D subjects in the
honeymoon phase were primarily dying through withdrawal of growth hormones with contribution of oxidative stress,
mitochondrial apoptotic pathways, and employment of TNF-receptor family members. Ab+ subjects, however, expressed
high inflammation level, which probably contributed to Treg apoptosis, although other apoptotic pathways were also
activated: withdrawal of growth hormones, oxidative stress, mitochondrial apoptosis and Fas/FasL apoptotic pathways. The
value of these results lie in potentially different preventive treatment subjects would receive depending on disease
progression stage when treated.
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Introduction
Type 1 Diabetes (T1D) is one of the most prevalent
autoimmune chronic diseases in children with a raising incidence
of ,3% annually [1,2]. T1D has a complex etiology as it is
influenced by multiple genetic and environmental risk factors. The
inherited genetic factors influence both susceptibility and resis-
tance to the disease [3,4]. The genetics of T1D has a long history
of studies evaluating candidate genes for association with disease
status using either case-control or family-based studies. These
studies revealed that the major susceptibility genetic locus for T1D
lies in the major histocompatibility complex (MHC) region
referred as IDDM1 [5]. The MHC region is located on the short
arm of chromosome 6 (6p21.3) spanning an interval of ,4 Mb.
Although the interval contains over 200 expressed genes [6],
candidate gene studies have implicated human histocompatibility
antigens (HLA) as being the primary T1D susceptibility locus [7,8].
The importance of the HLA region in the determination of T1D
risk was discovered in the 1970s [9]. Early family studies
comparing disease concordance in monozygotic twins and HLA-
matched siblings established the significance of HLA region genes
accounting for about 50% of the genetic risk [10].
Although extremely polymorphic [11], the major susceptibility
for T1D has been mapped to the HLA class II genes HLA-DQB1,
HLA-DQA1 and HLA-DRB1 [12,13]. The three genes have been
shown to independently contribute to T1D susceptibility with the
strongest single effect coming from HLA-DQB1 [3]. The
molecular basis for the association between at risk alleles and
T1D is still not clear. The HLA gene products are known to be
heterodimeric transmembrane glycoproteins that involve non-
covalently associated a- and b-chains, each having two extracel-
lular domains (a1 and a2o rb1 and b2). These molecules are
expressed on B lymphocytes, macrophages, and other cells of the
immune system termed antigen-presenting cells (APC) whose role
is to present antigens to T and B cells. Qualitative differences in
antigen presentation between the predisposing and the protective
DQ molecules coded by different alleles have been demonstrated
in functional studies, and these molecules are shown to contribute
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in pancreatic beta-cell destruction [14,15], suggesting that HLA
genes have an important role in antigen-specific regulation of T-
cell activation. However, HLA class II genes are also signaling
molecules leading to a variety of cellular responses including cell-
cell adhesion, proliferation, differentiation and apoptosis
[16,17,18,19]. CD4 T cells recognize HLA class II gene products
while CD8 T cells recognize HLA class I gene products. Variations
in HLA genes could, therefore, account for differential transcrip-
tional activities and quantities of mRNA of genes involved in the
activation/signal transduction. A quantitative hierarchy of DRB1
mRNA in healthy individuals has been observed for different
alleles (DRB1*03.DRB1*04.DRB1*01.DRB1*08) [20]. Similar
quantitative hierarchy has been observed for DQA1
(DQA1*0301.DQA1*0101.DQA1*0501) [21] and DQB1 genes
(DQB1*0301.DQB*0501.DQB1*0602) [22]. Over 90% of Cau-
casian diabetic subjects possess one of susceptibility haplotypes
HLA-DR4-DQA1*0301-DQB1*0302 or HLA-DR3-DQA1*0501-
DQB1*0201 or both [23,24,25]. The HLA-DR15-DQA1*0102-
DQB1*0602 haplotype is protective, and rarely present in T1D
subjects [26,27,28]. As polymorphisms in the DR and DQ genes
appear to be of great biological importance suggesting their
involvement in the etiology of the disease [4], HLA class II genes
are considered to be the best genetic markers for T1D [29]
currently available.
Our Wisconsin Family T1D Study involving non-related
random healthy controls, recent-onset (RO) T1D, healthy
autoantibody-positive (Ab+) siblings of T1D probands and long-
standing (LS) T1D subjects, has allowed us to develop an HLA
DQA1/B1 haplotype risk assessment tool that recognizes suscep-
tible (S), resistant (R), weakly protective (Y) and neutral haplotypes
(X). When these HLA DQA1/B1 haplotypes are combined into
haplogenotypes (please see table S1, and in ref [30]), they provide
information about HLA risk status with four categories: low,
moderate, high and very high risk [30]. These four categories we
further condensed into two-tier system, Low and High HLA risk
for easier comparison between T1D-related subject groups. We
found that there is a significant association of high HLA risk status
and T1D incidence in Wisconsin cohort, as .90% of affected
subjects possess High HLA risk haplotypes (Table 1). Our results
are consistent with previously published studies [24,25,31]. Earlier,
we have reported a correlation between High HLA risk haplotypes
and increased Treg apoptosis [30]. The present cross-sectional
study was designed to: 1) validate this result in larger sample of
subjects, 2) presents additional lines of evidence showing an
association between HLA gene expression and Treg apoptosis and
function, 3) assess change in Treg function during T1D
progression, and 4) assess activation of apoptosis pathways in T
cells.
Our results show that T1D will progress in those subjects where
increased Treg apoptosis is accompanied with decreased Treg
function. We also show that different apoptosis pathways are
prevalent during T1D progression. The value of these results lie in
potentially different preventive treatment subjects would receive
depending on disease progression stage when treated.
Materials and Methods
Healthy subjects
One hundred and seven subjects were recruited through the
diabetes program at Children’s Hospital of Wisconsin. Recent -
onset T1D subjects (after stabilization on exogenous insulin but
within 10 months of diagnosis; n=29) were recruited through the
diabetes program at Children’s Hospital of Wisconsin. Diabetes
was defined according to World Health Organization criteria and
included blood glucose levels of .200 mg/dl with symptoms
confirmed by a physician [32]. Healthy control (n=35) subjects
were recruited by posting flyers in Children’s Hospital of
Wisconsin and the Medical College of Wisconsin. The control
criteria comprised fasting blood glucose of ,100 mg/dl, no
familial history of any autoimmune disorder, and lack of islet
autoantibodies. We also recruited autoantibody-positive siblings of
T1D probands not included in this study (n=23) and longstanding
(LS) T1D subjects (n=20). All study subjects were free of known
infection at the time of sample collection. At the time of each visit,
the following clinical measurements were taken: HbA1c, glucose
level, height, weight and BMI (subject characteristics are shown in
Table 1). DNA was collected for HLA typing and presence of
autoantibodies was measured from peripheral blood. The research
protocol was approved by the Institutional Review Board (IRB) of
the Children’s Hospital of Wisconsin and participants and/or their
parents (guardians) provided written informed consent.
PBMC and FACS cell isolation
Peripheral blood mononuclear cells (PBMC) were collected
using vacutainers with ACD solution B of trisodium citrate and
isolation was done using Ficoll-Hypaque (Amersham Pharmacia,
Uppsala, Sweden) gradient density centrifugation according to the
recommended protocol. The PBMC were counted and stained
with a cocktail of fluorochrome conjugated monoclonal antibodies
in PBS (APC-aCD4 (clone RPA-T4), APC-Cy7-aCD25 or PE-
aCD25 (clone M-A251), FITC-aCD14 (clone M5E2), FITC-
aCD32 (clone FL18.26), FITC-aCD116 (cloneM5D12), PE-Cy7-
aCD8 (clone RPA-T8) all from BD Pharmingen, San Diego, CA)
and sorted on a FACSAria (BD Biosciences, San Diego, CA).
Using the same FACS isolation protocol described earlier [33], we
collected the top 1% of CD4
+CD25
high T-cells as Tregs. This
additional stringency of collecting just the top 1% of
CD4
+CD25
high cells as Tregs across subject groups ensured
removal of most of the activated CD25low T cells. CD4+ T cells
were further gated as CD4+252, CD4+25low and
CD4+CD25
high using the Fluorochrome Minus One (FMO)
method, which allowed for a more precise definition of cells
having fluorescence above the background level. The cells
expressing low levels of CD25 were collected and defined as
CD4+CD25low T cells. Based on performed assays, our isolation
protocol generated Tregs that maintained high level of sustained
FOXP3 expression associated with phenotypic and functional
stability. HLA DQ-PE (clone 1a3) antibody recognizing all DQ
alleles [34] was purchased from Leinco Technologies, Inc
(St.Louis, MO).
Cell culture and Suppression assay
CD4
+CD252 and CD4+CD25low T-cells (2.5610
4 cells/well)
were cultured in RPMI 1640 media supplemented with 2 mM L-
glutamine, 5 mM HEPES, 100 U/mg/ml penicillin/streptomycin,
0.5 mM sodium pyruvate and 10% human AB serum. Cells were
stimulated with aCD3 coated beads (1 mg/ml, 3 beads/cell) in U-
bottom 96-well plates (Costar) in the presence of the same number
of irradiated autologous PBMC for 3 days. For the suppression
assays Treg cells were co-cultured with responder T cells at a 1:10
ratio (Treg:Tresponder) using the same stimuli. Cells were pulsed
with 1 mCi of [
3H] thymidine (Amersham Pharmacia Biotech) and
harvested after 16 hours. The cpm per well was determined with a
scintillation counter (Top Count NXT, Packard). The percentage
of suppression was calculated as {(s2c)/s}6100%, where s=cpm
in single culture and c=cpm in co-culture.
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Genotyping of both HLA-DQA1 and HLA-DQB1 was
performed by direct sequencing of the polymorphic regions of
each gene. For HLA-DQA1, Exon 2 was sequenced, yielding a
low-resolution (2-digit) typing result. For HLA-DQB1, Exon 2 was
sequenced using SeCore DQB1 Locus Sequencing Kits (Invitro-
gen, Brown Deer, WI). This method yields high-intermediate (4-
digit resolution) of HLA-DQB1. HLA-DQA1-DQB1 haplotypes
and 4-digit resolution of HLA-DQA1 were then inferred using
Caucasian frequencies as reported by Klitz, et al. [35].
Apoptosis assay
Apoptosis was measured in CD4+CD252, CD4+CD25+low
and CD4+CD25+
high T cells immediately after FACS sorting for
baseline apoptosis levels and before exposure to any stimulation.
The cells were stained in the dark with 250 nM YOPRO1
(Molecular Probes, Eugene, OR) for 20 min and then 250 ng
7AAD (BD Biosciences) was added 10 min before acquiring at
least 10,000 events on LSRII FACS (BD Bioscience) machine. The
thresholds for both YOPRO1 and 7AAD were determined based
on the forward and side scatter properties of the naı ¨ve T cells.
Apoptosis was measured as the percentage of apoptotic cells
(YOPRO1
+/7AAD
2) among live cells (all 7AAD
2 cells compris-
ing both YOPRO1
+ and YOPRO1
2 cells)
PCR array of naı ¨ve and Treg cells
Apoptosis PCR array (SABiosciences, Frederick, MD) of naı ¨ve
and Treg cells was done on a subset of subjects involved in this
study: unaffected subjects in High HLA control group (n=8),
unaffected subjects in Low HLA control group (n=5), unaffected
multiple Ab+ subject group (n=4) and affected RO T1D (n=4).
Apoptosis PCR array used in this study was a 384-well (4696)
plate consisting of 84 key genes involved in programmed cell
death. There are 12 other wells set up for quality controls, for
example checking genomic DNA contamination, reverse tran-
scription efficacy and PCR array reproducibility. The plate set up
used in this study was done in pairs for every subject (naı ¨ve and
Tregs from the same subject) and, whenever possible, in pairs for
control and RO T1D/multiple Ab+ subjects. Gene expression of
Tregs from every subject was then normalized with gene
expression of autologous naı ¨ve T cells to account for expression
induced by common factors coming from, for example, T cell
lineage commitment or the procedure of cell isolation. Such
normalized values were then compared between groups. The
analysis of gene expression was done through comparison to Low
HLA risk healthy control subject group.
Real-Time PCR analysis
The second portion of isolated total RNA was converted to
cDNA using the QuantiTectH Reverse Transcription Kit (QIA-
GEN, Valencia, CA). Real-time PCR was then performed using
the QuantiTectH SYBR Green PCR Kit (QIAGEN) on an ABI
Prism 7900HT Sequence Detection System machine using SDS
software (Applied Biosystems, Foster City, CA). Manufacturer
protocols were followed for all procedures. RNA expression was
quantitated relative to 18S RNA expression. mRNA gene-
expression was quantitated relative to GAPDH mRNA expression.
Using the Oligo 6 software (Molecular Biology Insights), primer
sets for each gene were designed towards the same region of cDNA
that was represented by the probe sets on the Affymetrix
GeneChip arrays, and RT-PCR validation was performed.
In vitro inhibition of Treg apoptosis
Tregs isolated from random healthy control, RO T1D, Ab+
subjects and LS T1D subjects were treated either with soluble
FasL (1/40 dilution or 600 ng/ml) or with plate-bound aCD3
(clone UCHT1, Ancell) at high concentration (20 mg/ml) causing
activation-induced cell death (AICD). Separate cell aliquots were
pre-treated with Z-DEVD (caspase 3 inhibitor) or with Ac-IETD
(caspase 8 inhibitor) for 30 minutes before exposure to stimulation
with either soluble FasL or to AICD agent and apoptosis was
measured using YOPRO1/7AAD, as described above.
Statistics
The Mann-U-Whitney and Tukey-Kramer tests were used to
compare generated results between clinical groups, with p value
#0.05 considered significant. GraphPad software was used for
data presentation. We also performed Kruskal-Wallis test in
addition to a one-way ANOVA. Linear regression model was used
for association studies of Treg functional measurements (in vitro
suppression of proliferation of responder T cells) and HLA risk for
T1D.
Table 1. Demographic data of studied population.
Random Control Recent-onset T1D Auto-Ab+ Longstanding T1D p value
Number of subjects 35 29 23 20 NS
Average time after diagnosis (years) N/A* 0.5860.16 N/A* 2.6260.64 0.000871
Gender (% female) 54.3 42.8 54.5 42.8 NS
BMI at recruitment 22.7560.73 17.4760.76 20.9061.20 18.5161.00 ,0.001
Age at diagnosis (years) N/A* 10.8560.74 N/A* 9.6360.77 NS
Age at recruitment (years) 30.2262.75 12.0560.91 27.5863.16 12.0161.13 ,0.0001
Glucose at recruitment (mg/dl
21) 89.2661.91 163.31614.14 84.4161.14 162.87612.74 ,0.0001
HbA1c (%) N/A 7.0060.19 N/A 6.9760.32 NS
Insulin dose at recruitment (U/kg/day) N/A* 0.4060.03 N/A* 0.6260.05 ,0.0001
High HLA risk (%) 37.1 89.6 69.6 90 ,0.001
Treg apoptosis (%) 3.8460.49 15.5262.66 5.860.74 4.0460.45 ,0.0001
All data presented as (mean value)6SE; N/A – not available;
*- not applicable.
doi:10.1371/journal.pone.0036040.t001
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done as previously described [36]. Briefly, inspected RNA
degradation across all arrays showed no significant differences in
the degradation patterns. Quality control was done through visual
inspection of each microarray scan for irregularities, and the whole
microarray set was assessed using the ‘affyQCreport’ package from
the Bioconductor project (Halling et al, 2006). The quality of the
data was ascertained by inspecting various plots. Raw expression
values were normalized across all 27 samples by computing the
Robust Multichip Average (RMA) directly from the Affymetrix
.CEL files (Irrizary et al. 2003), generating expression measure on
the log base 2 scale.
Gene expression differences between RO T1D and control
samples were captured earlier using Affymetrix GeneChip human
genome U133 Plus 2.0 arrays. The experimental design, quality
control procedure, detailed statistical analysis and results are
described in [36].
Results and Discussion
This study involved subjects belonging to several cohorts aimed
at capturing different points of T1D progression, in an effort to
increase our ability to detect positive correlation between
generated results with T1D pathogenesis. These cohorts included:
unrelated healthy controls (no T1D), siblings of probands (not
included in this study) possessing multiple Ab+ (in a stage of
developing T1D), recent-onset (RO) T1D (experienced T1D
onset, but in the honeymoon phase when endogenous insulin
production temporarily improves) and longstanding (LS) T1D
subjects (fully dependent on exogenous insulin) (Table 1). Each of
these subject groups was also tested for correlation of the results
relative to HLA risk. For this comparison, we gathered data
capturing changes at the genetic, genomic or transcriptional as
well as at protein and functional level in different cell subsets,
isolated by Fluorescent Activated Cell Sorting (FACS). Thus, we
present here several lines of evidence that confirm differences in
monitored traits between Low and High HLA risk subjects when
divided according to T1D status.
HLA risk associated with Treg apoptosis levels
As HLA has been recognized as a major genetic risk factor,
subject groups involved in this study were partitioned into two
HLA risk groups (Low and High) according to the scheme we have
developed earlier [30]. We have linked Treg apoptosis with HLA
risk for T1D in our previous study [30] and in this study we verify
the trend in a larger sample of subjects (Figure 1A). Partitioning of
healthy controls and RO T1D subjects on Low and High HLA
risk groups (High involving Moderate, High and Very High HLA
risk groups), reveals increased Treg apoptosis levels in High HLA
risk control subjects when compared to their Low HLA risk
counterparts, while Treg apoptosis difference between the two
HLA risk groups has not been seen in RO T1D subject group.
This suggests that in healthy control subjects there is an association
of HLA risk with Treg apoptosis. In disease state, however, T1D
progression overrides this association, increasing Treg apoptosis
levels further independently of HLA risk. High HLA risk status
was associated with increased Treg suppressive function in Control
group, most likely offering an explanation of why High risk control
subjects do not succumb the disease. High HLA risk RO T1D
group had significantly lower Treg function compared to High
HLA risk healthy controls (Figure 1B). In a search for better
understanding the association of HLA and Tregs, we have also
measured frequency of healthy control and RO T1D subjects’
Tregs expressing surface HLA DQ molecules (Figure 1C).
Significantly higher frequency of Tregs from High HLA risk RO
T1D subjects expressed surface DQ alleles compared to Tregs
from High HLA risk healthy control subjects (p=0.001). It has
been acknowledged that, when activated, T cells also express HLA
molecules on their surface [37]. The HLA DQ expression on Tregs
implies potential antigen presentation to other T cells [38,39,40]
encouraging belief that T-T cell interactions play an important
role in the immune response [41].
Putting together HLA risk with Treg apoptosis and function in
four different subject cohorts as representative of stages during
T1D development, has shown changes in their correlation
(Figure 2). Increased Treg suppressive function directly correlated
with Treg apoptosis up to 6% in High HLA risk healthy control
and LS T1D subject groups. The opposite was true for RO T1D,
where higher suppressive function in High HLA risk RO T1D
subjects correlated with lower Treg apoptosis. There was no
significant correlation between the three factors in multiple Ab+
subjects. These findings prompted us to look into differences in
HLA expression on Treg cells as well as mechanisms of Treg
apoptosis.
Differential expression of HLA class II genes might be
impacted by HLA risk and/or disease progression
We conducted gene expression profiling of un-manipulated,
FACS isolated ex vivo Treg cells in the two most clinically distinct
subject groups, healthy Control (n=15) and RO T1D subjects
(n=12) and using GeneChipH Human Genome U133 Plus 2.0
array (Affymetrix, Santa Clara, CA) (data not shown here but
deposited as GEO in [36]). In this report, the primary discussion
was on the expression of apoptosis genes across RO T1D and
controls. Although downregulation of HLA Class II genes in RO
T1D was also observed in the results, this observation was not
discussed in that report. In the current report, we highlight this
down-regulation of HLA genes (HLA DQA1, DQB1, DRA1,
DRB1 with fold changes of 25.3, 21.9, 22.2 and 21.6,
respectively) and validate those results by RT-PCR (Figure 3A
and 3B). The goal here is to better understand processes involved
in T1D pathogenesis relative to the expression of HLA genes. RO
T1D subjects express lower levels of HLA genes class II compared
to healthy control subjects, with HLA DQB1 reaching significance
(p=0.04). When both subject groups were divided according to
HLA risk using our simplified scheme (Low and High HLA risk),
opposite trend was noticed for control and RO T1D subjects.
Namely, High HLA risk healthy controls showed higher
expression of HLA DQB1, DRA1 and DRB1 compared to Low
HLA risk control group, while opposite was true for RO T1D.
Low HLA risk RO T1D had significantly higher expression of the
three HLA class II genes compared to High HLA risk RO T1D
subjects (Figure 3B). The same trend of the HLA class II genes’
expression was detected in CD25low T cells (data not shown),
suggesting effect of disease on the expression of HLA genes in all T
cells without exerting cell specificity.
Our observation of reduced overall expression of HLA DR and
DQ molecules in freshly isolated Tregs from RO T1D brings up
an interesting but yet unexplored aspect of ‘inducible’ HLA
expression and its role in Treg phenotype and function. It is not
completely clear if HLA gene expression, the frequency of T cells
expressing HLA molecules or the magnitude of expressed HLA
molecules on the surface of T cells is relevant to the pathogenesis
of diabetes. HLA Class II genes are constitutively expressed only on
some cells (for example, antigen-presenting cells), but there is
evidence of inducible HLA expression in several other cells,
including Tregs [42]. The fact that we detected co-ordinated
down-regulation of several HLA genes in disease could be
Treg Apoptosis Pathways in Type 1 Diabetes
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more transcription factors common across all genes within each
HLA group. Analysis of the promoter regions of HLA class II
genes, with the search restricted to locate transcription factors
common across four HLA class II genes (DRA1, DRB1, DQA1
and DQB1) showed two transcription factors (NFYA and NFAT)
down-regulated in Tregs from T1D subjects compared to healthy
control subjects (0.93-fold, p=0.12 and 0.97-fold, p=0.045,
respectively). Although expression differences in fold change were
subtle, downregulation of NFAT in RO T1D has reached
significance (p=0.045). Interestingly, NFYA, which is a transcrip-
tion factor regulating both Class I and Class II genes (HLA class I
genes were also downregulated, data not shown) is located in the
6p21.31 region, roughly 8.4MB centromeric to T1D-linked HLA
DQB1 gene. Indeed, it was reported that NFYA participates in
regulation of class II genes in activation-specific manner [43].
Significantly downregulated NFAT expression in RO T1D versus
healthy control subjects could offer an explanation for reduced
HLA expression we report here and IL-2 deprivation we reported
earlier [36], considering that NFAT is a downstream molecule in
IL-2 signaling pathway. NFAT is transcription factor important in
the lifecycle not only effector T cells (forming complex with AP-1)
but also in Tregs (forming complex with Foxp3). Namely, crystal
structure of an NFAT:FOXP:DNA complex reveals an extensive
protein-protein interaction interface between NFAT and FOXP
family of proteins [44]. Thus, by switching transcriptional
partners, NFAT converts the acute T cell activation program into
the suppressor program of Tregs [44]. There is evidence that HLA
expression can be induced in an environment rich in inflammatory
cytokines [45,46], suggestive of type of environment in the islets of
a person progressing towards total beta-cell destruction. Further-
more, as human T lymphocytes are one of cell types that express
HLA class II molecules following activation, these molecules on
activated T cells could either affect the activity of T cells or they
could provide signals that modulate T-cell functioning. If
allogeneic dendritic cells expressing HLA-DQ (not HLA-DR)
stimulate naı ¨ve T cells, they will shift towards Th2 phenotype [46].
As both HLA-DQ and HLA-DR genes, latter known as an
activation marker, are down-regulated in Tregs from T1D
subjects, it is possible that in T1D subjects, Tregs in the periphery
have an activation defect, due to which they fail to exert
suppressive function. Similar problem could affect effector T cells,
causing lower IL-2 production leading to IL-2 deprivation,
increased Treg apoptosis and decreased Treg function. Indeed,
Figure 1. Treg apoptosis, function and surface HLA DQ relative to HLA risk in healthy control and RO T1D subjects. A) Healthy High
HLA risk control subjects show significantly increased Treg apoptosis levels (ANOVA F=10.24 df(3,64), p,0.0001). Detailed significance presented in
the figure done using Mann-U-Whitney test. However, RO T1D subjects that succumbed disease show significantly increased Treg apoptosis levels
independently on HLA risk. B) High HLA risk healthy control subjects show significantly increased suppressive function of their Tregs compared to
Low HLA risk controls (Mann-U-Whitney test, p=0.01), while that association was lost in RO T1D group (Mann-U-Whitney, p=0.69). C) RO T1D
subjects with High HLA risk haplotypes show significantly higher surface DQ expression compared to Low HLA risk both RO T1D and healthy control
subjects while High HLA risk healthy controls express the least number of cells with surface HLA DQ (ANOVA F=14.62 df(3,20), p,0.0001). Detailed
comparisons was done using Mann-U-Whitney test. Values are presented with standard errors.
doi:10.1371/journal.pone.0036040.g001
Figure 2. Changes in correlation of HLA risk with Treg apoptosis and Treg function in subject cohorts representing stages of T1D
development. In High HLA risk both healthy control and LS T1D subjects, increased Treg apoptosis significantly correlated with increased Treg
function (p=0.017 and p=0.042, respectively). High HLA risk RO T1D subjects showed opposite correlation: increased Treg apoptosis was correlated
with decreased Treg function (p=0.027). Multiple Ab+ subjects did not show correlation between Treg apoptosis and function in High HLA risk group
(p=0.95). Although some trends were present, Low HLA risk groups did not show correlation with Treg apoptosis and function.
doi:10.1371/journal.pone.0036040.g002
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T1D subjects proliferated less compared to control subjects (data
not shown). Beside the current study, few other studies have
focused on the expression of HLA molecules in T cells of patients
with T1D, reporting unequal expression of HLA DQA1 and DQB1
alleles in total peripheral PBMC of T1D patients [47,48].
Common and different apoptosis pathways activated
during T1D pathogenesis
In the light of observations of increased Treg apoptosis in High
HLA risk subjects compared to Low HLA risk group (Figure 1A),
we were specifically interested in the expression of genes involved
in apoptosis pathways with a goal to identify potential differences
in activated apoptotic pathways associated with T1D pathogenesis.
PCR Arrays were used to measure expression of 84 genes of
known apoptotic pathways in un-manipulated ex vivo naı ¨ve and
Treg cell subsets from High HLA risk Control subject group
(n=8), Low HLA risk control subject group (n=5), RO T1D
patients (n=4) and multiple Ab+ subjects (n=4). Gene expression
of Tregs from every subject was normalized with gene expression
of the same genes in autologous naı ¨ve T cells to account for
expression induced by common factors coming from, for example,
T cell lineage commitment or the procedure of cell isolation. Such
normalized values were then compared between groups. The
analysis of gene expression in each subject group (High HLA
control, RO T1D, and multiple Ab+) was done through
comparison to Low HLA risk healthy control subject group.
The analysis of resultant gene expressions between each subject
group relative to Low HLA risk (Figure 4A) showed few commonly
overexpressed genes across RO T1D, multiple Ab+ and High
HLA risk control subjects: Bik, CARD6, caspase2, TNFRSF11B
and caspase 14. Tregs from all subject groups overexpressed
caspase 2, known as initiator caspase, relative to Low HLA risk.
This result is in agreement with our cellular assay showing
increased Treg apoptosis in all those subject groups relative to Low
HLA risk group suggesting activation of caspase-dependent
apoptosis pathway(s). As a highly conserved and tightly controlled
process, apoptosis involves activation of many other genes as well.
A recent publication indicated the necessity of BID expression in
the commitment to apoptosis, which is one of pro-apoptotic
members of Bcl-2 family [49],. Indeed, compared to Low HLA
risk healthy control subjects, both RO T1D and Ab+ subject
groups (showing the highest Treg cell apoptosis levels) had
increased expression of both caspase 4 and BID genes in Tregs
versus Low HLA risk Tregs.
Each of the three subject groups with increased Treg apoptosis
also overexpressed a unique set of genes (Figure 4B). Interestingly,
some of overexpressed genes among both RO T1D and Ab+
subjects were genes with anti-apoptotic function (RO T1D
overexpressed Akt1 (.24-fold), Bag1 (.331-fold) and Mcl-1
(.266-fold) and Ab+ overexpressed BIRC6 (.467-fold), BIRC2
(.14-fold) and Bcl2L1 (.13-fold), suggesting that Tregs are trying
to counteract strong pro-apoptotic signal. Additionally, different
anti-apoptotic molecules are probably activated at different points
in T1D pathogenesis, most likely as a response to different
apoptotic stimuli.
FADD (adaptor molecule associated with apoptosis) was the only
uniquely upregulated gene in High HLA control group when
compared to both Low HLA risk and RO T1D (.8-fold and .14-
fold, respectively), implying the prevalent Treg apoptosis path-
way(s) in this subject group. Interestingly, High HLA risk subject
group consists of healthy subjects that have not succumbed T1D
despite increased Treg apoptosis. The explanation might lie in
apoptosis pathway activated in this subject group. We noticed that
many pro-apoptotic genes were overexpressed in both RO T1D
and Ab+ subjects (TNFRSF9, TNFRSF10B, PYCARD, caspases 3, 7
and 9, BIRC8, BCLAF1, Bak1, and APAF1, Figure 4C). In addition,
gene coding TNFRSF11b (OPG), indirectly involved in apoptosis
process, was expressed 34.5-fold more in High HLA risk control
compared to Low HLA risk control subjects. This gene acts as
decoy receptor for both TRAIL and RANKL [50], and reacts
through it to FADD, that was, as mentioned earlier, uniquely
overexpressed (.8-fold) in Tregs of High HLA risk subjects,
transmitting an inhibitory signal to NFkB and affecting many
biological processes. Although OPG was upregulated in RO T1D
and Ab+ subjects, lack of FADD overexpression suggests that
OPG might in these subject groups react with different ligand
potentially increasing Treg apoptosis through different pathways
compared to High HLA risk control subjects. Furthermore, it has
been shown that inflammatory cytokines elevate OPG expression
and release [51]. Intriguingly, OPG is involved in development
and function of dendritic cells [52,53]. All subjects also showed
increased expression (52-fold) of caspase recruitment domain family,
Figure 3. RT PCR verification of microarray data of HLA class II genes expression in Tregs isolated from Control and RO T1D
subjects. A) HLA DR and DQ gene expression differences between control (n=8) and RO T1D (n=7) subjects. Only expression of DQB1 reached
statistically significant difference (p=0.045). B) Both Control (light grey bars) and RO T1D (red bars) subjects were divided according to HLA risk (see
Table S1) and compared for expression of HLA genes. While High HLA risk (cross-pattern bars) control subjects had significantly higher expression of
DRA1 compared to Low risk (empty bars, Mann-U-Whitney test, p=0.045) Controls, Low HLA risk RO T1D subjects had higher expression of DRA1, but
also DQB1 and DRB1 compared to corresponding High HLA risk RO T1D (Mann-U-Whitney test, p=0.03, p=0.03 and p=0.01, respectively). Values are
presented with standard errors.
doi:10.1371/journal.pone.0036040.g003
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members (like NOD1-CARD4 and Cardiak-Rick or Rip2)
suppressing activation of NFkB, but not interfering with their
ability to induce caspase1-dependent secretion of interleukin-1b
[54]. Deprivation of survival cytokines and the presence of
inflammatory cytokines with additional overexpression of Fas/
FasL could further increase Treg apoptosis in these groups of
subjects as a results of disease progression. Gene expression profile
for genes on PCR array done for High HLA risk control group
suggests that increased Treg apoptosis is mostly happening via
caspase-dependent pathways, more precisely, through involvement
of receptors upregulating FADD, but without participation of Fas
and FasL, which were downregulated in this subject group when
compared to Low HLA control group (,294-fold and ,217-
fold, respectively).
RO T1D Tregs overexpressed pro-apoptotic Bcl2-family genes
(.2299-fold Bcl2L10 and .25-fold Bax) Figure 4B), as well as
anti-apoptotic genes (.266-fold Mcl1 and .331-fold Bag1) and
caspase 14, which might act as an anti-apoptotic molecule due to
suppressive nature of its interaction with apoptosis-inducing factor
[55]. This suggests desperate attempts Tregs make to recover and
counteract already initiated apoptosis process. Uniquely expressed
TRAF2, TRADD and TNFRSF1A genes in Tregs of RO T1D
subjects suggest activation of apoptosis through TNF-family
members.
Genes expressed differentially in Ab+ subject group relative to
Low HLA risk are presented in Figure 4B. The fact that expression
of caspase 5 was 425-fold higher than in Low HLA risk group
suggests that inflammation is substantial at this point of T1D
progression. Furthermore, Ab+ subject group overexpresses
several pro-apoptotic Bcl2-family members (Bcl2L11 - 17.5-fold,
NOD1 – 33.6-fold, Bik – 21.2-fold, Bax – 11.5-fold, Bid – 10.3-
fold and Bad – 4-fold) while Bcl2L1 (Bcl2XL, .13-fold), BIRC2
(.14-fold) and BIRC6 (.467-fold) counteracted pro-apoptotic
signals. This coordinated overexpression of Bcl2 family members
suggests that prevalent apoptotic pathway in Ab+ subjects heavily
involve mitochondria. Overexpression of Bcl2L11 (Bim) suggests
apoptosis initiation through withdrawal of growth hormones,
supporting findings of other studies [36,56]. Ab+ subjects
expressed TNFRSF21/25 (,15-fold of both), suggesting involve-
ment of TNF pathway to total Treg apoptosis.
Based on gene expression profile of PCR array discussed above
supported by ex vivo and in vitro assays, Tregs of High HLA risk
subjects differ from autologous naı ¨ve T cells by higher cell
turnover completed through a caspase-dependent process that
involves molecules transmitting a signal via FADD. On the other
hand, analysis of genes expressed in multiple Ab+ subjects suggests
that apoptosis is occurring through overexpression of multiple pro-
apoptotic members of Bcl2 family, as their dimerization results in
changes in mitochondrial membrane potential, release of cyto-
chrome C and imbalance in production of reactive oxygen species
(ROS), causing oxidative stress [57,58]. Oxidative stress has been
implicated with both onset and the progression of T1D [59].
Additionally, healthy Ab+ subjects, some of which are already on
the path of developing T1D [60], show substantially increased
expression of caspase 4 and 5 (.151-fold and .425-fold,
respectively), suggestive of an extensive inflammation and
overexpression of caspase 2 (.112-fold), whose role was recently
expanded to a translational cofactor for DNA damage-induced
p21 expression [61].
Overexpression of pro-apoptotic genes from Bcl-2 family was
even more pronounced in RO T1D compared to Ab+ subjects
(Figure 4A). Literature suggests that production of ROS causes
inhibition of complex enzymes of mitochondrial respiration and
accumulation of unfolded protein response (UPR) within endo-
plasmic reticulum (ER) [62,63]. Increasing body of evidence
suggests that cytokines [64], fatty acids [65,66] and glucose [67,68]
could induce ER and mitochondrial stress, which play an
important role in pathogenesis of diabetes at the level of neural,
immuno-, and pancreatic beta cells [69,70]. Mitochondrial and
ER stress contribute to increased Treg apoptosis in these groups of
subjects. The role of Bcl2 family members (great number of which
we have detected) in mitochondrial membrane permeabilization
has been proven by their ability to induce cytochrome C release
from mitochondria triggering the caspase cascade ending with cell
degradation [71]. Additionally, Tregs isolated from RO T1D
subjects show increased expression of TRAF2, reported to have an
essential role in oxidative stress-induced cell death triggered by ER
stress [72,73]. RO T1D expressed TRAF2 .23-fold and FasL
.7-fold compared to healthy Low HLA risk subject group
(Figure 4) causing increased transmission of death signal further,
most likely via JNK arm activating apoptosis in Treg cells [74].
Figure 4. Differential gene expression in the three subject groups relative to Low HLA risk group. Ratio of gene expression between
Tregs and CD252 from each subject was first obtained and averaged for each group before comparison to the Low HLA risk control subject group. A)
fold change genes expression in the High HLA risk healthy control (n=8), Ab+ subjects (n=4), RO T1D subjects (n=4), relative to Low HLA risk
subject group (n=5), B) fold change of genes uniquely expressed in RO T1D (red bars), Ab+ subjects (dark grey bars) and High HLA risk subjects (light
grey bars) relative to Low HLA risk group. C) Genes downregulated in High HLA risk group compared to Low HLA risk group. Cutoff value for
presentation of overexpressed genes was .5-fold. * - anti-apoptotic genes.
doi:10.1371/journal.pone.0036040.g004
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particular, inflammatory processes, mitochondrial and ER stress all
converge in caspase - induced apoptosis of Tregs, leading to T1D
onset. In Ab+ subjects that have not yet experienced T1D onset, the
degree of expression and activation of these genes, which depends
on cytokine milieu, will dictate time distance to T1D onset for those
subjects, making this period of time particularly important in terms
of preventive immunomodulatory treatment. Since our data show
that Tregs from both RO T1D and Ab+ subjects die through Fas/
FasL pathway, and the opposite was true for High HLA control
subjects, we chose this stimulation to validate our microarray and
PCR array results. We thus performed in vitro cell-based assay where
both naı ¨ve and Tregs were treated either with soluble FasL (1/40
dilution or 600 ng/ml) for 20 hours (Figure 5A), and proceed
further treating Tregs with either soluble FasL treatment or with
TCR stimulation, both with and without pretreatment with caspase
inhibitors (Figure 5B and C). Knowing that these two apoptosis
inductions activate caspase cascade [75], we chose to pretreat cells
with caspase 3 (Z-DEVD) and caspase 8 (Ac-IETD) inhibitors. As
shown on Figure 5A, manipulated (FasL-treated) Tregs from RO
T1D subjects (as well as naı ¨ve T cells) were significantly more
susceptible to FasL-initiated apoptosis pathways compared to High
HLA risk healthy control subjects (Mann-U-Whitney test,
p=0.016, Figure 5A), which was in concordance with our PCR
array finding, showing noticeable Fas/FasL downregulation in ex
vivo Tregs from High HLA risk control subjects (Figure 4A).
Studying Tregs isolated from healthy individuals with no consid-
eration of their HLA risk, Fritzsching reported higher sensitivity of
Tregs to Fas-mediated apoptosis and lower to that mediated by
TCR [76]. In our study, Tregs from healthy Low HLA risk only
were responsive to Fas-mediated apoptosis (data not shown), while
High HLA risk control subjects showed the opposite apoptotic
phenotype, suggesting that HLA might have not yet recognized role
in receiving an apoptosis signal. This hypothesis warrents additional
studies. In an attempt to abrogate Treg apoptosis in FasL- and the
AICD-induced apoptosis pathway, Z-DEVD or Ac-IETD were (or
not) used for 30 minutes pre-treatment of Tregs in vitro in Low HLA
risk controls, RO T1D and Ab+ subject groups (presented together
in Figure 5B and C). In vitro FasL treatment significantly increased
Treg apoptosis through involvement of caspase 3, as apoptosis was
significantly lowered by pretreatment with caspase3 inhibitor Z-
DEVD in all subjects except in RO T1D subjects (depicted by red
symbols throughout Figure 5). Since Treg apoptosis in RO T1D
subjects was more efficiently prevented after pretreatment with
caspase 8 inhibitor Ac-IETD, quite expectedly showing that the
apoptosis pathway in RO T1D subjects was triggered through
membrane receptors (Figure 5B). This result clearly suggests more
significant involvement of caspase 8 rather than caspase 3 in the
FasL-triggered apoptosis pathway in Tregs from RO T1D subjects
during honeymoon period. AICD apoptosis activated both caspase
3 and 8 at comparable levels across subject groups.
In conclusion, our data sheds new light on evolving Treg
apoptosis pathways and function during T1D development and
suggests the importance of HLA in this process. Our results
support our hypothesis about the triangular association of HLA
risk, Treg survival and Treg function to suggest that different
stages in T1D development activate diverse prevalent apoptosis
mechanisms, probably as a result of changing surrounding factors
impacting further progression towards T1D. This information
could be useful when choosing preventive treatment for subjects at
different stages of diabetogenesis (either at risk to develop T1D or
after T1D onset while in honeymoon phase). Combined with our
Treg apoptosis/function methods, apoptosis pathway analysis
offers valuable information about potential selection of an
immunomodulatory treatment that could prevent further T1D
progression in these subject groups. Unquestionably, our results of
prevalent Treg apoptotic pathways associated with T1D develop-
ment warrant further investigation. One type of future study could
be a clinical trial employing an agent tailored to block prevalent
mechanism(s) in each of the stages of T1D development where our
assays would monitor treatment effects in real time.
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Figure 5. Fas/FasL T-cell apoptosis prevalent in RO T1D, LS T1D and Low HLA risk controls. A) In vitro soluble FasL caused significantly
lower T cell apoptosis (in both naı ¨ve-CD25 and Tregs) in healthy High HLA risk control subjects compared to RO T1D T cells (for both cell subset
comparisons Mann-U-Whitney test was p=0.016), suggesting that Fas/FasL is one of the prevalent apoptosis mechanism in RO T1D subjects, but not
in High HLA risk control subjects. B) Treg apoptosis caused by soluble FasL (1/40 dilution – 600 ng/ml) in healthy control, RO T1D and LS T1D subjects
was significantly reduced with pretreatment with caspase 3 inhibitor Z-DEVD in majority of subjects. However, analysis of RO T1D subjects alone (red
symbols) showed their better responsiveness to pretreatment with Ac-IETD compared to Z-DEVD. C) Activation-induced Treg apoptosis by anti-CD3
was moderately prevented through treatment of both inhibitors, suggesting an involvement of both caspase 3 and 8 in this apoptosis pathway in all
subject groups. RO T1D subjects were labeled with red symbols. Mann-U-Whitney test was used for comparisons.
doi:10.1371/journal.pone.0036040.g005
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